ReviewBioMed research international2015
Calcium channel expression and applicability as targeted therapies in melanoma.
Review in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- The mechanosensitive TRPV2 calcium channel promotes human melanoma invasiveness and metastatic potential.EMBO reports · 2023Article
- Suppressing Effect of NaInternational journal of molecular sciences · 2022Article
- Concomitant Antihyperalgesic and Antitumor Effects of Gabapentin in a Murine Cancer Pain Model.International journal of molecular sciences · 2021Article
- Inhibition of the Human Hsc70 System by Small Ligands as a Potential Anticancer Approach.Cancers · 2021Article
- mMolecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- Article
- Cyclovirobuxine D inhibits cell proliferation and migration and induces apoptosis in human glioblastoma multiforme and low‑grade glioma.Oncology reports · 2020Article
- Review
- Article
- Molecular classification and subtype-specific characterization of skin cutaneous melanoma by aggregating multiple genomic platform data.Journal of cancer research and clinical oncology · 2018Article
- Cav3.1 overexpression is associated with negative characteristics and prognosis in non-small cell lung cancer.Oncotarget · 2018Article
- The Effect of Gap Junctional Coupling on the Spatiotemporal Patterns of Ca2+ Signals and the Harmonization of Ca2+-Related Cellular Responses.PLoS computational biology · 2016Article
- Chronic activation of the D156A point mutant of Channelrhodopsin-2 signals apoptotic cell death: the good and the bad.Cell death & disease · 2016Article
- Corrigendum to "Calcium Channel Expression and Applicability as Targeted Therapies in Melanoma".BioMed research internationalArticle
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The remodeling of Ca(2+) signaling is a common finding in cancer pathophysiology serving the purpose of facilitating proliferation, migration, or survival of cancer cells subjected to stressful conditions. One particular facet of these adaptive changes is the alteration of Ca(2+) fluxes through the plasma membrane, as described in several studies. In this review, we summarize the current knowledge about the expression of different Ca(2+) channels in the plasma membrane of melanoma cells and its impact on oncogenic Ca(2+) signaling. In the last few years, new molecular components of Ca(2+) influx pathways have been identified in melanoma cells. In addition, new links between Ca(2+) homeostasis and specific cell processes important in melanoma tumor progression have been unveiled. Thus, not only do Ca(2+) channels appear to have a potential as prognostic markers, but their pharmacological blockade or gene silencing is hinted as interesting therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.